Bioprocessing

A common misconception among many researchers and biotech startup founders is that bioprocess development is straightforward.

Dr. David Brühlmann

CMC Strategist

Bioprocessing

A common misconception among many researchers and biotech startup founders is that bioprocess development is straightforward.

Dr. David Brühlmann

CMC Strategist

Key Topics Discussed

The Bioprocess Brief — biweekly intelligence for CMC and manufacturing leaders.

Strategic takeaways on biologics, cell and gene therapies, and AI-driven bioprocessing — distilled from the Smart Biotech Scientist Podcast and 20+ years on the floor.

Scientific breakthroughs in molecular biology often receive the spotlight, while the industrialization of these discoveries is seen as secondary or even easy. The move from lab-scale innovation to full-scale industrial production is one of biotech’s most complex, expensive, and misunderstood challenges.

Biotech success depends not only on scientific novelty but also on the ability to scale those discoveries into robust, compliant, and efficient manufacturing processes. Without this translation into an industrial framework, the benefits of groundbreaking discoveries remain out of reach for patients and the market.

This concept is discussed in greater detail with Alfredo Martínez Mogarra in an episode of the Smart Biotech Scientist Podcast, hosted by David Brühlmann.

 

People and Collaboration: The Heart of Biotech Facilities

A biotech facility is only as effective as the people who run it. Coordinating manufacturing, quality, engineering, and supply chain requires more than technical skill—it requires culture.

Effective collaboration starts with the separation of thought and action:

  • Operational teams focus on executing tasks with minimal disruption.
  • Cross-functional leadership aligns decisions, shares trends, and anticipates issues.

The operations team should include:

  • Manufacturing operators
  • QA/QC specialists
  • Process and automation engineers
  • Supply chain managers

Establishing shared goals, routine communication, and respect between disciplines helps avoid the all-too-common tension between “quality” and “production.”

Choosing Suppliers and Equipment

Selecting the right equipment and suppliers is a matter of long-term reliability, not short-term cost savings.

Key selection criteria:

  • Fit for Purpose: Define precise specifications based on process needs, not off-the-shelf brochures.
  • Support and Maintenance: Choose suppliers with proven regional support and maintenance coverage.
  • Regulatory Readiness: Ensure GMP compliance, transparency, and qualification capabilities.

Transitioning to Routine Manufacturing

Once operations begin, the focus shifts to stability and predictability. Like brewing beer, industrial biotech requires consistent inputs and controlled environments.

To ensure long-term success:

  • Identify critical manufacturing indicators
  • Use control charts to track trends and deviations
  • Investigate drifts proactively before they trigger failures

An MSAT (Manufacturing Science and Technology) team plays a crucial role in this process, driving continuous improvement, analyzing trends, and informing decision-making.

Embracing Digital Tools and Automation

Digitalization and automation must be integral to the facility’s vision from day one. Even if implementation comes later, foundational systems should be planned early.

Start with:

  • ERP Systems: Track materials, inventory, and warehouse status
  • SCADA Systems: Enable equipment monitoring and process control
  • Digital Documentation: Integrate electronic batch records, quality control logs, and document systems

Evaluate automation based on:

  • Task frequency and labor intensity
  • Impact on consistency and safety
  • Long-term cost-benefit analysis

The Role of AI and Machine Learning

AI is still evolving in bioprocessing, but its potential is enormous. When trained on process data, AI can identify hidden relationships between material attributes and final product quality.

Read More: The Case For Digital Hybrid Modeling In Bioprocess Development

Possible applications include:

  • Bioreactor performance modeling
  • Predictive control and simulation
  • Early identification of variability drivers

Although still in development, these tools provide a data-driven approach to optimizing processes previously governed by intuition or trial and error.

Avoiding the Pitfalls

Technology dependency comes with risks, particularly in a volatile geopolitical and supply chain environment. Concentrated suppliers, microchip shortages, or political conflict can create bottlenecks. Additionally, biotech remains a high-risk industry, with high failure rates and long ROI timelines. 

Investors and operators must remain aware of:

  • Supply chain fragility
  • Capital risks
  • Technology adoption lags

Final Remarks

The most important message from decades of experience is this: think deeply before you act. Planning, anticipation, and scenario modeling make the difference between operational chaos and long-term success.

Every process has its scale-up surprises. Every facility poses new constraints. However, with rigorous design, risk analysis, and collaboration, biotech facilities can be built to function and thrive.

Next Step

If you found value in today’s episode, take a moment to like, follow, and leave a review on Apple Podcasts or your favorite platform—it helps us reach and support more scientists like you.

Thanks for tuning in to the Smart Biotech Scientist podcast and being part of this journey toward bioprocess mastery. For more insights and practical tips, visit

www.smartbiotechscientist.com

About Alfredo Martínez Mogarra

Alfredo Martínez Mogarra is a bioprocess engineer with a background in biology and over 30 years of experience in the biotech industry. He has worked with leading companies across Spain, Europe, and the USA, including Amgen, Serono (now Merck), and Genzyme (now Sanofi).

Alfredo has participated in the design, construction, and start-up of multiple manufacturing facilities in various countries and has broad expertise in process improvement for a wide range of molecules

Connect with Alfredo Martínez Mogarra on LinkedIn.

Further Listening

If you enjoyed this episode you might also like listening to:

Episodes 205 - 206: Process Economics Decoded: How to Model Biomanufacturing Costs From Clinical to Commercial Scale with Niklas Jungnelius

Episodes 139 - 140: Regulatory Secrets Revealed: Why Your CMC Strategy Could Make or Break Your Biotech Startup with Rivka Zaibel

Episodes 03 - 04: How to Master Biotech Scale-up Without Guesswork with Leonardo Sibilio

Episodes 233 - 234: Why Most Bioprocess Automation Projects Fail Before the Robot Is Even Ordered with Anthony Catacchio

Want to Join?

Are you a CMC or biomanufacturing leader with hard-won lessons on process development, scale-up, or CDMO management? We’re always looking for practitioners with real execution stories to share on Smart Biotech Scientist.

Apply to be a guest or recommend someone:  

hello@smartbiotechscientist.com


David Brühlmann is a strategic advisor who helps C-level biotech leaders reduce development and manufacturing costs to make life-saving therapies accessible to more patients worldwide.

He is also a biotech technology innovation coach, technology transfer leader, and host of the Smart Biotech Scientist podcast—the go-to podcast for biotech scientists who want to master biopharma CMC development and biomanufacturing.  

Hear It From The Horse’s Mouth

Want to listen to the full interview? Go to Smart Biotech Scientist Podcast. 

Want to hear more? Do visit the podcast page and check out other episodes. 
Do you wish to simplify your biologics drug development project? Contact Us

Liked this article?
Get the next one in your inbox.

The Bioprocess Brief — biweekly digests and deep-dives on biologics, cell and gene therapies, and AI-driven bioprocessing, written by a CMC practitioner.

Key Topics Discussed

The Bioprocess Brief — biweekly intelligence for CMC and manufacturing leaders.

Strategic takeaways on biologics, cell and gene therapies, and AI-driven bioprocessing — distilled from the Smart Biotech Scientist Podcast and 20+ years on the floor.

Latest Blogs

Field-tested articles on CMC strategy, scale-up, tech transfer, and GMP readiness, for teams turning biologics into market-ready therapies.

Innovation

10,000 Structures Are Not Enough: The Data Gap Limiting De Novo Antibody Design – Part 2

Innovation

10,000 Structures Are Not Enough: The Data Gap Limiting De Novo Antibody Design – Part 1

Innovation

Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge – Part 2